New Drug Applications

Ocular Therapeutix Announces NDA Resubmission of Dextenza

8 years ago
by David Miller
965 Views
Written by David Miller

BEDFORD, Mass.–(BUSINESS WIRE)–Jun. 29, 2018– Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye,…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts
[mwai_chat window="true" fullscreen="true"]